Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): Significant short term improvement

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Horneff, Gerd ^a   Fitter, Sigrid ^a   Foeldvari, Ivan ^b   Minden, Kirsten ^c   Kuemmerle Deschner, Jasmin ^d   Tzaribacev, Nicolay ^e   Thon, Angelika ^f   Borte, Michael ^g   Ganser, Gerd ^h   Trauzeddel, Rolf ⁱ   Huppertz, Hans Iko ^h  

^a Asklepios Klinik   (Germany)

^b Klinikum Eilbek   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Klinikum Bad Bramstedt   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g Klinikum St Georg   (Germany)

^h St Josef Stift Sendenhorst ^*  (Germany)

ⁱ HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; PLACEBO; PREDNISONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADOLESCENT DISEASE; ANKYLOSING SPONDYLITIS; APPENDICITIS; ARTICLE; BACK PAIN SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SPINAL INFLAMMATION SCORE; BATH AS FUNCTIONAL INDEX; CHILD; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTRITIS; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; JUVENILE ONSET ANKYLOSING SPONDYLITIS; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TENDINITIS; VERTIGO; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DISABILITY; DOSE RESPONSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; CHILD; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867686547     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4072     Document Type: Article

References (42)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41:58-67. 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G, 9433870.
2. Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am 1997, 23:569-598. 10.1016/S0889-857X(05)70348-3, 9287378.
3. Baek HJ, Shin KC, Lee YJ, Kang SW, Lee EB, Yoo CD, Song YW. Juvenile onset ankylosing spondylitis (JAS) has less severe spinal disease course than adult onset ankylosing spondylitis (AAS): clinical comparison between JOAS and AAS in Korea. J Rheumatol 2002, 29:1780-1785.
4. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
5. Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 2005, 53:445-451. 10.1002/art.21174, 15934110.
6. Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 2008, 67:233-237. 10.1136/ard.2007.072512, 17604288.
7. O'Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD. Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis. Ann Rheum Dis 2009, 68:1407-1412. 10.1136/ard.2008.092304, 18782793.
8. Garcia-Morteo O, Maldonado-Cocco JA, Suarez-Almazor ME, Garay E. Ankylosing spondylitis of juvenile onset: comparison with adult onset disease. Scand J Rheumatol 1983, 12:246-248. 10.3109/03009748309098542, 6623013.
9. Horneff G, Burgos-Vargas R. TNF-α antagonists for the treatment of juvenile-onset spondylarthritides. Clin Exp Rheumatol 2002, 20(Suppl. 20):137-142.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2001, 31:390-392.
11. Davis JC, van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236. 10.1002/art.11325, 14613288, Enbrel Ankylosing Spondylitis Study Group.
12. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. 10.1002/art.21913, 16802350, ATLAS Study Group.
13. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:82-91.
14. Roguska MA, Keegan M, Labkovsky B. The nucleotide sequence of LU 200134, and a description and complete nucleotide sequence of the LU 200134 mammalian expression vector. In-house report - BASF Bioresearch Corporation: BBC/M 9607+9713.
15. Sakorafas P, Kaymakcalan Z. Characterization of LU 200134: recombinant human TNFα interaction kinetic rate constants by real-time biospecific interaction analysis (BIA). BASF Bioresearch Corporation. Report No. BBC/I 9602.
16. Patil S. Pharmacokinetic evaluation: a supplement to final clinical study report DE005. In-house report, Knoll Pharmaceutical Company: DE005-PK.
17. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A, , Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359:810-820. 10.1056/NEJMoa0706290, 18716298, Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation.
18. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 2003, 4:526.
19. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104. 10.1056/NEJMoa011110, 11596589.
20. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155. 10.1016/S1473-3099(03)00545-0, 12614731.
21. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004, 31:2055-2061.
22. Horneff G, Schmeling H, Moebius D, Foeldvari I. Efficacy of etanercept in active refractory juvenile spondylarthropathy: prospective open study of 40 patients [abstract]. Arthritis Rheum 2004, 50(Suppl 9):S91.
23. Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int 2004, 24:173-176. 10.1007/s00296-003-0378-0, 14648110.
24. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009, 76:24-27. 10.1016/j.jbspin.2008.03.008, 19070529.
25. Lovell DJ, Giannini EH, Reiff A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Eng J Med 2000, 342:763-769.
26. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003, 48:218-226. 10.1002/art.10710, 12528122.
27. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1638-1644. 10.1136/ard.2003.014886, 1754849, 15115709, Paediatric Rheumatology Collaborative Group.
28. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68:519-525. 10.1136/ard.2007.087593, 18413440.
29. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003, 62:245-247. 10.1136/ard.62.3.245, 1754468, 12594111.
30. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886. 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F, 11508441.
31. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
32. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DR, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
33. Ruof J, Sangha O, Stucki G. Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 1999, 58:218-225. 10.1007/s003930050174, 10502022.
34. Reiff A, Henrickson M. Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis. Arthritis Rheum 2001, 44:S292.
35. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005, 52:2103-2108. 10.1002/art.21121, 15986366.
36. Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R, Vazquez Mellado J. A twelve week, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of infliximab in juvenile-onset spondyloarthritis (Jo-SpA). Ann Rheum Dis 2008, 67(Suppl ii):69-70.
37. Ansell BM, Hall MA, Loftus JK, Woo P, Neumann V, Harvey A, Sills JA, Swinson D, Insley J, Amos R. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991, 9:201-203.
38. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Luijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA. Sulfasalzin in the treatment of juvenile chronic arthritis. A randomized double-blind placebo-controlled multicenter study. Arthritis Rheum 1998, 41:808-816. 10.1002/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T, 9588731.
39. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernández-Garduño A, Goycochea-Robles MV. A 26 week randomised, double-blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002, 61:941-942. 10.1136/ard.61.10.941, 1753917, 12228171.
40. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, Veys EM. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, doubleblind, placebocontrolled study. Arthritis Rheum 1995, 38:1218-1227. 10.1002/art.1780380907, 7575715.
41. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gömör B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006, 65:1147-1153. 10.1136/ard.2006.052878, 1798286, 16606646.
42. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31. 10.1136/ard.2010.133645, 21109520.